Acquired Company

Aeglea BioTherapeutics completed the acquisition of Spyre Therapeutics on June 22, 2023 in a stock-for-stock transaction.

Spyre Therapeutics Inc., based in Waltham, Massachusetts, is a pioneering biotechnology company dedicated to the development of novel antibody therapies specifically targeting inflammatory bowel disease (IBD). The company harnesses cutting-edge antibody engineering and precision medicine to fulfill substantial unmet medical needs within IBD management, establishing a strong foothold in this niche therapeutic market. With a promising clinical pipeline and a commitment to improving patient outcomes through personalized medicine, Spyre Therapeutics presents a compelling investment opportunity for institutional investors focused on innovative healthcare solutions. Show more

Location: 221 CRESCENT STREET, WALTHAM, MA, UNITED STATES, 02453, Waltham, MA, 02453, USA | Website: https://www.spyre.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

2.556B

52 Wk Range

$10.91 - $35.31

Previous Close

$32.94

Open

$33.77

Volume

790,548

Day Range

$33.16 - $35.21

Enterprise Value

2.336B

Cash

64.9M

Avg Qtr Burn

-37.12M

Insider Ownership

6.78%

Institutional Own.

86.31%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
SPY072 (SPY002-072) Details Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SPY003 Details Ulcerative colitis	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SPY002 (SPY002-091) (TL1A) Details Inflammatory bowel disease, Ulcerative colitis	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SPY001 (α4β7) Details Crohns disease, Inflammatory bowel disease	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.